Clinical Research Directory
Browse clinical research sites, groups, and studies.
cfDNA Methylation for Liver Cancer Recurrence Detection
Sponsor: Wuhan Ammunition Life-tech Co., Ltd
Summary
Through follow-up testing of patients with primary liver cancer who underwent hepatectomy, liver transplantation, ablation therapy, or transarterial chemoembolization (TACE), a blinded comparative trial was conducted at each monitoring site. This trial evaluated the combined methylation detection kit for GNB4 and Riplet genes (fluorescent PCR method) against the clinical reference standard (defined as the physician's comprehensive diagnosis based on clinical guidelines and other criteria). The study evaluated the clinical performance of the assay in diagnosing primary liver cancer recurrence and validated the clinical efficacy of methylation detection kits for monitoring recurrence after primary liver cancer treatment.
Official title: Clinical Study on the Combined Detection of Plasma GNB4 and Riplet Gene Methylation for Monitoring Primary Liver Cancer Recurrence
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
OBSERVATIONAL
Enrollment
500
Start Date
2025-09-02
Completion Date
2027-12-31
Last Updated
2026-03-23
Healthy Volunteers
No
Conditions
Interventions
plasma GNB4 and Riplet genes methylation detection
Liver cancer patients undergo methylation testing at different follow-up time points after treatment
Locations (1)
Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, China